<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Champions' PDX Models Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496

A Champions Case Study

Identifying and developing targeted oncology compounds is often an arduous, costly, and time-consuming process. As the demand for effective personalized oncology therapies grows, so does the need for a more predictive model solution.

The value of Champions' Lumin Analytics database is demonstrated in our latest case study, which shows how the utilization of our PDX models in a screening and efficacy evaluation impacted the development of a novel compound, the dual BRAF-EGFR inhibitor, CEP-32496.

Download the Case Study